- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Dr Jeff Patton on OCM PP3 Results, Challenges With the Model
Jeff Patton, MD, chief executive officer of Tennessee Oncology, discusses results from Oncology Care Model (OCM) performance period 3 (PP3) and challenges his practice still experiences with the model.
Jeff Patton, MD, CEO of Tennessee Oncology, discusses results from Oncology Care Model (OCM) performance period 3 (PP3) and challenges his practice still experiences with the model.
Transcript
With results from PP3 of the OCM now out, how did your results compare with PP2?
We have 4 pillars of trying to impact value in OCM; we do clinical pathways, we have nurse navigation, we have a triage platform, and we do palliative care. Through those, in each performance period, we’ve increased our savings. We’ve beat our benchmark every time, we’ve not hit the target, and so we haven’t had shared savings. But, every time, we’ve increased. PP3, we had 2.5% of savings. Now, if you remember, that includes the MEOS [Monthly Enhanced Oncology Services] payments, which is about 3%, so if you exclude the MEOS payments, we’ve saved 5.5% in the total cost of care. So, we’re excited about our results and going forward.
What are the most pressing challenges your practice still experiences with OCM and its reporting requirements?
You said it—the reporting requirements are probably the most onerous. We also think that risk stratification is not right and there’s some flaws there. And then the third and maybe the biggest is the novel therapy adjustment. If you’re an early adopter of a novel therapy, you get penalized. Even though there’s an adjustment, it’s an 80% adjustment, so by definition, you’re 20% in the hole with only an 80% adjustment. We think being penalized for being innovative is just not fair.
Could On-Body Delivery of Isatuximab Bring More Competition to Anti-CD38 Myeloma Treatment?
June 6th 2025Results for IRAKLIA show noninferiority for Sanofi's on-body delivery system for isatuximab, compared with IV administration. Patients overwhelmingly preferred the hands-free delivery option.
Read More
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
Zanubrutinib Shows Durable Benefit for High-Risk CLL/SLL at 5 Years in SEQUOIA Trial
June 6th 2025Zanubrutinib showed long-term efficacy in patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) and deletion of the 17p chromosome, with progression-free survival similar to patients without high-risk disease characteristics.
Read More
Promoting Equity in Public Health: Policy, Investment, and Community Engagement Solutions
June 28th 2022On this episode of Managed Care Cast, we speak with Georges C. Benjamin, MD, executive director of the American Public Health Association, on the core takeaways of his keynote session at AHIP 2022 on public health policy and other solutions to promote equitable health and well-being.
Listen
Real-World Data Support Luspatercept vs ESAs for Anemia in Lower-Risk MDS
June 5th 2025Patients with myelodysplastic syndrome (MDS) who received luspatercept showed greater hemoglobin gains and transfusion independence compared with erythropoiesis-stimulating agents (ESAs) in a real-world analysis.
Read More
At EHA 2025, Hematology Discussions Will Stretch Across Lifespans and Locations
June 5th 2025The 2025 European Hematology Association (EHA) Congress, convening virtually and in Milan, Italy, from June 12 to June 15, 2025, will feature a revamped program structure for the meeting’s 30th anniversary while maintaining ample opportunities to network, debate, and absorb practice-changing findings in hematology and oncology.
Read More
